PFIZER INC
PFE evidence brief
What we can confirm
- BioSniper Score:
- 9.2 / 10
- Market Cap:
- $158.39B
- Lead Asset:
- abrilada (Approved)
What it means
What to watch
Prepared research question
What matters most for PFE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PFE
Pfizer Inc. is a global pharmaceutical company transitioning beyond COVID-19 revenues, with a late-stage pipeline focused on obesity (berobenatide), oncology (Seagen assets, atirmociclib), and immunology (LITFULO, tilrekimig), while facing a patent cliff through 2030.
Key risk: Patent cliff through 2030
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 28, 2026.
Tracking 28 pipeline candidates · 212 clinical trials · 13 catalysts · 23 FDA decisions for PFIZER INC.
Pfizer Inc. is a global pharmaceutical company transitioning beyond COVID-19 revenues, with a late-stage pipeline focused on obesity (berobenatide), oncology (Seagen assets, atirmociclib), and immunology (LITFULO, tilrekimig), while facing a patent cliff through 2030.
- Reported total revenue of $15,034M and net loss of -$248M for the period ending 2026-06-28 [sec].
- Cash and equivalents of $976M as of 2026-06-28 [sec].
- Positive Phase 3 results for LITFULO in nonsegmental vitiligo reported in August 2026, with plans for global regulatory filings [news · 2026-08-04].
- Phase 2b data for berobenatide (monthly GLP-1 agonist for obesity) showed proof of concept; Phase 3 trials have started [news · 2026-06-15].
- Pipeline includes over 100 candidates, with about 20 pivotal trial starts planned in 2026 across oncology and metabolic disease [news · 2026-03-26].
What works
- Obesity pipeline gaining traction: berobenatide (monthly GLP-1) has started Phase 3 trials with favorable tolerability data [news · 2026-06-15].
- Oncology growth supported by Seagen acquisition and positive Phase 2 results for atirmociclib in metastatic breast cancer [news · 2026-04-08][news · 2026-03-26].
- Immunology wins with positive Phase 3 LITFULO data in vitiligo and encouraging topline data for tilrekimig in eczema [news · 2026-08-04][news · 2026-03-26].
- Strong balance sheet with shareholders' equity of $85,190M as of 2026-06-28 [sec].
What to weigh
- Patent cliff approaching: key patents for tofacitinib citrate (2028, 2034), dacomitinib (2032), and talazoparib tosylate (2031) will expire, pressuring revenue [catalyst].
- Net loss of -$248M reported for the period ending 2026-06-28, indicating ongoing profitability challenges [sec].
- COVID-related revenues declining, with the halt of a key COVID vaccine trial and lower COVID product sales [news · 2026-04-08].
- Cash position of $976M is relatively modest for a large pharma, potentially limiting flexibility for large acquisitions [sec].
From the filings
Quoted directly from source documents.
Positive Phase 3 results for LITFULO in vitiligo
“Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo.”
News · August 4, 2026
Berobenatide Phase 2b data showed proof of concept
“The data show proof of concept with favorable tolerability and low reported adverse events in the trial setting.”
News · June 15, 2026
Pipeline includes over 100 candidates
“Pfizer reports a pipeline of more than 100 candidates, alongside cost cutting efforts and balance sheet adjustments during this transition phase.”
News · April 8, 2026
Catalyst timeline
- 2026-10-09 · Phase3_Start: PF-08634404 in combination with chemotherapy for advanced endometrial cancer — Initiation of a Phase 3 open-label study evaluating PF-08634404 plus chemotherapy vs pembrolizumab plus chemotherapy in mismatch repair proficient endometrial cancer.
- 2027-06-07 · Patent_Expiry: Fesoterodine fumarate — Patent expiry for fesoterodine fumarate (NDA022030), potentially opening market to generics.
- 2027-12-12 · Patent_Expiry: Naltrexone HCl; Oxycodone HCl — Patent expiry for the combination product (NDA207621), allowing generic competition.
- 2028-08-21 · Patent_Expiry: Tofacitinib citrate — Patent expiry for tofacitinib citrate (NDA213082), a key immunology drug.
- 2031-10-20 · Patent_Expiry: Talazoparib tosylate — Patent expiry for talazoparib tosylate (NDA211651), an oncology PARP inhibitor.
- 2032-09-27 · Patent_Expiry: Dacomitinib — Patent expiry for dacomitinib (NDA211288), an oncology drug.
- 2034-03-14 · Patent_Expiry: Tofacitinib citrate (additional) — Secondary patent expiry for tofacitinib citrate (NDA208246).
- 2034-06-26 · Patent_Expiry: Zavegepant HCl — Patent expiry for zavegepant hydrochloride (NDA216386), a migraine treatment.
Risks & what to watch (4)›
Key risks
- Patent cliff through 2030 — Key patents for tofacitinib, dacomitinib, and talazoparib expire between 2028 and 2034, risking revenue erosion [catalyst].
- COVID revenue decline — Lower COVID-related revenues and halted vaccine trial pressure near-term financials [news · 2026-04-08].
- Net loss in latest period — Reported net loss of -$248M as of 2026-06-28, indicating profitability challenges [sec].
- Modest cash reserves — Cash of $976M is low for a large pharma, limiting strategic flexibility [sec].
What to watch
- Phase 3 data and regulatory filings for LITFULO in vitiligo [news · 2026-08-04].
- Phase 3 progress and future data for berobenatide in obesity [news · 2026-06-15].
- Oncology pipeline readouts, including atirmociclib and Seagen assets [news · 2026-03-26][news · 2026-07-14].
- Patent expiry dates for key drugs starting in 2028 [catalyst].
Sources: Catalysts · News · Generated October 8, 2026 · How we verify sources →
Run PFIZER INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PFIZER INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.36 · 0% dilution
Lead: Approved
28 candidates
13 upcoming, next in ~236d
3 buys · 2 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 2.4%
- Days to cover
- 3.5
- Shares short
- 133,414,052
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PFE short interestGovernance
Frequently asked questions
What is the AI investment thesis for PFIZER INC?
Pfizer Inc. is a global pharmaceutical company transitioning beyond COVID-19 revenues, with a late-stage pipeline focused on obesity (berobenatide), oncology (Seagen assets, atirmociclib), and immunology (LITFULO, tilrekimig), while facing a patent cliff through 2030.
What is PFIZER INC's lead drug candidate?
PFIZER INC's most advanced tracked candidate is abrilada (Approved).
What is PFIZER INC's next catalyst?
PFIZER INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA022030" — expected June 7, 2027.
Who is the CEO of PFIZER INC?
Dr. Albert Bourla D.V.M., Ph.D. is the chief executive officer of PFIZER INC (PFE).
Where is PFIZER INC headquartered?
PFIZER INC (PFE) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.